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Abstract
Introduction The idea that multidrug resistance (MDR) to
antibiotics in pathogens causing ventilator-associated
pneumonia (VAP) is an independent risk factor for adverse
outcome is still debated. We aimed to identify the determinants
of MDR versus non-MDR microbial aetiology in VAP and
assessed whether MDR versus non-MDR VAP was
independently associated with increased 30-day mortality.
Methods We performed a retrospective analysis of a
prospectively registered cohort of adult patients with
microbiologically confirmed VAP, diagnosed at a university
hospital intensive care unit during a three-year period.
Determinants of MDR as compared with non-MDR microbial
aetiology and impact of MDR versus non-MDR aetiology on
mortality were investigated using multivariate logistic and
competing risk regression analysis.
Results MDR pathogens were involved in 52 of 192 episodes
of VAP (27%): methicillin-resistant Staphylococcus aureus in
12 (6%), extended-spectrum β-lactamase producing
Enterobacteriaceae  in 28 (15%), MDR Pseudomonas
aeruginosa and other non-fermenting pathogens in 12 (6%).
Multivariable logistic regression identified the Charlson index of
comorbidity (odds ratio (OR) = 1.38, 95% confidence interval
(CI) = 1.08 to 1.75, p = 0.01) and previous exposure to more
than two different antibiotic classes (OR = 5.11, 95% CI = 1.38
to 18.89, p = 0.01) as predictors of MDR aetiology. Thirty-day
mortality after VAP diagnosis caused by MDR versus non-MDR
was 37% and 20% (p = 0.02), respectively. A multivariate
competing risk regression analysis showed that renal
replacement therapy before VAP (standardised hazard ratio
(SHR) = 2.69, 95% CI = 1.47 to 4.94, p = 0.01), the Charlson
index of comorbidity (SHR = 1.21, 95% CI = 1.03 to 1.41, p =
0.03) and septic shock on admission to the intensive care unit
(SHR = 1.86, 95% CI = 1.03 to 3.35, p = 0.03), but not MDR
aetiology of VAP, were independent predictors of mortality.
Conclusions The risk of MDR pathogens causing VAP was
mainly determined by comorbidity and prior exposure to more
than two antibiotics. The increased mortality of VAP caused by
MDR as compared with non-MDR pathogens was explained by
more severe comorbidity and organ failure before VAP.
Introduction
Ventilator-associated pneumonia (VAP) is a major infectious
complication in critically ill patients in terms of its incidence
and associated mortality and morbidity [1-4]. A clinical suspi-
cion of VAP is responsible for the majority of antibiotic pre-
scription in the intensive care unit (ICU) [5]. Estimates of
attributable mortality of VAP range from 0% to as high as 50%
[6], and this variability is thought to depend on several factors
such as admission diagnosis of patients in the study, severity
of illness at the time of VAP, type of microbial pathogen and
APACHE: Acute Physiology and Chronic Health Evaluation; ARDS: Acute Respiratory Distress Syndrome; CFU: colony forming units; CI: confidence 
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whether appropriate antibiotic treatment is provided in a timely
manner [7-10].
Microbial pathogens involved in VAP are frequently multidrug
resistant (MDR), which challenges the appropriateness of
empirical antibiotic prescription [10]. Furthermore, MDR
inflates antibiotic consumption because it necessitates empir-
ical use of broad-spectrum antibiotics, often in combination
therapy [1], and it hampers subsequent de-escalation of this
therapy [11]. Several authors have observed increased mortal-
ity in VAP caused by MDR pathogens as compared with other
bacterial pathogens, which they have attributed to a higher risk
of initial inappropriate antibiotic therapy in these patients [10-
13] or to increased intrinsic virulence of the pathogen [14,15].
Others have taken the alternative view that increased mortality
in MDR VAP is largely due to confounding [16-19] by the pref-
erential occurrence of MDR infection in a subset of ICU
patients with a priori decreased odds for survival, that is, those
patients with a prolonged duration of mechanical ventilation
and previous antibiotic treatment [20].
In the present study, we aimed to identify the risk factors for
MDR as compared with non-MDR microbial aetiology of VAP,
and tested the hypothesis that MDR, as compared with non-
MDR, aetiology of VAP is an independent predictor of mortality
using a multivariate competing risk analysis according to the
methodology of Fine and Gray [21].
Materials and methods
Study design, patients and clinical setting
To examine the determinants of mortality, a prospective cohort
study was performed recruiting all patients with microbiologi-
cally confirmed VAP during a three-year period (1 April 2004
to 31 March 2007) in our 54-bed medical and surgical ICU of
the 1060-bed Ghent University Hospital. To address the
determinants for MDR bacterial aetiology of VAP, we per-
formed a subsequent case-control study of patients with MDR
VAP. Patients with VAP caused by non-MDR pathogens acted
as controls. All patients aged 16 years and older and venti-
lated for at least 48 hours were assessed daily for evidence of
VAP. Patients who were chronically mechanically ventilated
were excluded. Only microbiologically confirmed episodes of
VAP were considered for analysis. The study was approved by
the Ethics Committee of Ghent University Hospital. Written
informed consent to obtain patients' data was given by the
patient or the patient's representative if the patient was unable
to give consent.
Routine microbiological work-up of airway samples consisted
of rapid Gram-staining and semi-quantitative culturing of tra-
cheal aspirate. On clinical request (in cases of discrepancy
between likely clinical diagnosis of VAP and semi-quantitative
microbiological results), quantitative culturing was performed
on tracheal aspirate or on broncho-alveolar lavage fluid
obtained by means of fibre-optic bronchoscopy. Plate quanti-
tation for semiquantitative cultures and use of selective media
to identify MDR pathogens was performed as described pre-
viously [22,23]. Semiquantitative scoring was derived from
streaking and diluting the specimen in three segments, scored
as few (+-) for less than 10 colonies, light (+), moderate(++)
and heavy (+++) growth when moderate to heavy growth was
observed in first, second and third streaks respectively. Antibi-
otic susceptibility was determined according to methods rec-
ommended by the Clinical and Laboratory Standards Institute
[24].
At our hospital, initial antibiotic therapy in ICU-acquired infec-
tion is guided by surveillance cultures, as described previously
[22,23,25]. At clinical diagnosis of VAP, the following antibiot-
ics were prescribed if surveillance cultures did not grow Pseu-
domonas aeruginosa or MDR organisms: a second-
generation cephalosporin or amoxicillin-clavulanic acid in
pneumonia diagnosed within one week or less after ICU
admission of a patient without prior antibiotic exposure; or an
antipseudomonal  β-lactam in patients with prior antibiotic
exposure or an ICU stay of more than one week. If additional
risk factors for P. aeruginosa were present (e.g. bronchiecta-
sis, corticosteroid therapy) or if P. aeruginosa was isolated
from surveillance cultures, an antipseudomonal β-lactam treat-
ment was complemented with an aminoglycoside or fluoroqui-
nolone. In patients with surveillance cultures growing MDR
organisms, initial antibiotic therapy, consisting of an antipseu-
domonal  β-lactam antibiotic or carbapenem was comple-
mented by a glycopeptide, fluoroquinolone or aminoglycoside
as appropriate; alternatively, targeted therapy directed at the
MDR pathogen was provided.
Data collected
Data collected at ICU admission included demographics,
admission diagnosis, presence of comorbidity, severity of ill-
ness on admission as assessed by Acute Physiology and
Chronic Health Evaluation (APACHE) II score, presence of
coma (defined by Glasgow Coma Scale (< 6) and develop-
ment of circulatory shock on ICU admission (defined as
requirement of vasopressor therapy after restoring intravascu-
lar volume within 48 hours of ICU admission). Presence of
comorbidity was quantified using the Charlson index of comor-
bidity [26], as described previously [24,27].
Data collected at diagnosis of VAP were prior duration of
mechanical ventilation (days), prior antibiotic therapy within
the same hospitalisation period, number of infectious epi-
sodes and number of different antibiotic classes prescribed.
We recorded a diagnosis of underlying Acute Respiratory Dis-
tress Syndrome (ARDS) and underlying acute kidney injury
requiring renal replacement therapy, if present at least two
days (day -2) before VAP, and the presence or absence of
shock on ICU admission. Clinical pulmonary infection score
(CPIS) was calculated at suspicion of VAP to corroborate clin-
ical diagnosis [28]. Microbial aetiology was recorded if availa-Available online http://ccforum.com/content/12/6/R142
Page 3 of 10
(page number not for citation purposes)
ble (see definitions below). Sequential Organ Failure
Assessment (SOFA) score was calculated on the day of diag-
nosis of VAP, as well as at day -2 and two days after (day +2)
diagnosis of VAP. The SOFA score is a scoring system quan-
tifying the extent of a critically ill patient's organ dysfunction or
failure, and is composed of six subscores, one each for the
respiratory, cardiovascular, hepatic, coagulation, renal and
neurological systems [29].
Antibiotic prescription on diagnosis of VAP was noted: antibi-
otic prescription on the same calendar day and the calendar
day after clinical diagnosis of VAP was considered as antibi-
otic therapy within 24 hours and 48 hours of VAP, respec-
tively. Primary outcome parameter was 30-day mortality after
diagnosis of VAP.
Definitions
VAP was considered clinically likely if a new or progressive
and persistent infiltrate was present on chest X-ray together
with at least two signs of systemic inflammation, such as fever
with a temperature higher than 38°C or hypothermia with a
temperature lower than 36°C, leucocytosis (>11,000 white
blood cell count (WBC)/mm3) or leucopenia (<4000 WBC/
mm3), rising C-reactive protein (> 2 mg/dL within 48 hours),
and with at least one sign of local inflammation such as puru-
lent sputum and a decrease of partial pressure of oxygen in
arterial blood (PaO2)/fraction of inspired oxygen (FiO2) of at
least 10%. Moreover, a CPIS of at least six was required to
maintain diagnosis of clinically likely VAP [28].
Clinically likely VAP was considered as microbiologically con-
firmed if: a pathogen showed ++ or +++ semiquantitative cul-
ture or more than 105  colony forming units (CFU)/mL
quantitative growth on a good quality endotracheal aspirate;
growth of ++ semiquantitative culture of more than 104 CFU/
mL on broncho-alveolar lavage fluid; growth of at least +
together with positive Gram-staining if antibiotic therapy had
been initiated or changed within 48 hours before sampling; or
when a pathogen was isolated both from endotracheal aspi-
rate and blood cultures. Based on a previous in-house analysis
where semiquantitative and quantitative cultures on endotra-
cheal aspirate correlated well (data not shown), and sup-
ported by other reports, we rely both on semiquantitative and
quantitative cultures for microbiological confirmation of VAP
[30,31]. If more than one pathogen grew above the semiquan-
titative or quantitative threshold, VAP was considered pol-
ymicrobial and if at least one MDR pathogen grew above these
thresholds, VAP was considered as MDR.
The following pathogens were considered as MDR: methicillin-
resistant Staphylococcus aureus (MRSA), extended-spectrum
β-lactamase producing Gram-negative Enterobacteriaceae
(ESBL), Pseudomonas aeruginosa and other non-fermenting
organisms (Acinetobacter baumannii, Stenotrophomonas mal-
tophilia) resistant for three or more of the following antibiotic
classes: antipseudomonal cephalosporins or penicillins, car-
bapenems, fluoroquinolones and aminoglycosides (MDR NF).
Antimicrobial therapy within 24 hours and 48 hours of diagnosis
of VAP was considered appropriate if it included at least one
antimicrobial drug with in vitro activity against the aetiologic
agent identified. ARDS was defined according to the criteria of
the American-European consensus conference [32], and shock
was defined as the requirement of vasopressor therapy
(noradrenaline or adrenaline) to restore adequate arterial pres-
sure and organ perfusion despite appropriate intravenous fluid
substitution.
Statistics
Continuous variables are described as mean (± standard devi-
ation), median (25th to 75th percentile) and categorical varia-
bles are described as n (%). For comparative tests on
continuous variables, the Mann-Whitney U test and student's
t-test were used as appropriate, depending on variable distri-
bution. For categorical variables, the Pearson chi-square test
or the Fisher's exact test were used as appropriate. The
response variable used in the mortality analyses was vital sta-
tus (alive or dead) 30 days after diagnosis of VAP. In patients
with multiple episodes of VAP, only the first microbiologically
confirmed VAP was retained for further analysis. Logistic
regression analysis was used to assess the multivariate rela-
tion between multiple patient characteristics and the probabil-
ity of involvement of MDR as compared with non-MDR
pathogens in VAP. To adjust for the association of MDR ver-
sus non-MDR microbial aetiology on 30-day mortality after
diagnosis of VAP on potential confounders and to check
whether MDR is a independent predictor, we performed a
competing risk analysis using the Fine and Gray model [21],
with 30-day mortality after diagnosis of VAP as the endpoint of
interest, and discharge alive from the hospital within 30 days
after diagnosis of VAP as the competing risk.
Recently some authors discussed the application of these
recently developed models in the specific ICU-setting where
censoring due to discharge alive from the ICU violates the
assumption of non-informative censoring [33,34]. Conse-
quently, standard survival methods which rely on non-informa-
tive censoring appear not to be appropriate here [35,36]. As
the primary aim was to determine whether MDR constituted an
independent risk factor for mortality in the presence of other
covariates, the enter method was primarily used, comple-
mented with stepwise forward and backward analysis to test
stability of the models. Overall, predictors showing a p < 0.1
association with in-hospital mortality in univariate analysis as
well as those variables that seemed clinically important were
incorporated in the regression analyses. Correlation matrixes
for all predictors included in the regression analyses were con-
structed to avoid inclusion of significantly associated sets of
predictors and to limit the risk of colinearity.Critical Care    Vol 12 No 6    Depuydt et al.
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When appropriate, odds ratios (OR) and 95% confidence
intervals (CI) were reported, and the Hosmer-Lemeshow
goodness-of-fit test and the area under the curve of the result-
ing receiver operator curve were provided. Results from the
competing risk analysis were reported as sub-hazard ratios,
which are the ratios of hazards associated with the cumulative
incidence function. The various models were tested for the
presence of clinically significant interaction. Statistical analy-
ses were executed with SPSS 11.0 (SPSS Inc. Chicago, IL)
and the R 2.6.2 software package [37]. The competing risk
analysis was performed using the crr routine available in the
cmprsk package developed by Gray [38]. All tests used were
two-tailed and statistical significance was defined as p < 0.05.
Results
During the study period, microbiologically confirmed VAP was
diagnosed in 192 patients. MDR pathogens were isolated in
52 of 192 (27%) first episodes and in 11 of 34 (32%) subse-
quent episodes of VAP. Systematic oral, nasal, urinary and rec-
tal surveillance cultures obtained within the first 48 hours of
ICU admission revealed presence of MDR pathogens in seven
patients (4%). Of the 192 patients included in the study, 47
patients (24.5%) died within 30 days of VAP diagnosis. The
estimated cumulative incidence function of death was 16.6%
on day 10 and 24.5% on day 30. For the competing risk (dis-
charged alive from the hospital) the estimated cumulative inci-
dence function was 32% and 54%, respectively (Figure 1).
Risk factors for involvement of MDR pathogens in VAP
Characteristics of patients with VAP caused by MDR versus
non-MDR pathogens are provided in table 1, as well as the
predominant pathogen identified. The univariate odds ratio for
isolating a MDR pathogen in patients previously exposed to an
increasing number of antimicrobial classes is shown in figure
2. Rates of appropriate antibiotic therapy achieved within 24
hours and 48 hours after diagnosis of VAP were lower in
patients with MDR as compared with other pathogens, and
30-day, ICU- and in-hospital mortality were significantly higher
in patients with VAP caused by MDR than in patients with non-
MDR VAP.
Results of the multivariable analysis of predictors of MDR as
compared with non-MDR microbial aetiology of VAP are
shown in table 2. We included exposure to one, two and more
than two antibiotic classes (with no prior antibiotics as refer-
ence category), together with duration of mechanical ventila-
tion (days) prior to VAP as predictors, as these are known risk
factors for MDR [20], as well as those predictors that showed
a significant association (p < 0.1) in univariate analysis. Expo-
sure to more than two antibiotic classes during hospitalisation
before VAP diagnosis was significantly associated with MDR
aetiology in enter and backward stepwise regression analysis.
Figure 1
Cumulative incidence function of death 30 days after diagnosis and of  being discharged alive Cumulative incidence function of death 30 days after diagnosis and of 
being discharged alive.
Figure 2
Odds ratio for risk of multidrug-resistant microbial aetiology of ventila- tor-associated pneumonia Odds ratio for risk of multidrug-resistant microbial aetiology of 
ventilator-associated pneumonia. Odds ratio for risk of multidrug-
resistant (MDR) microbial aetiology of ventilator-associated pneumonia 
(VAP) with increasing previous antibiotic exposure, expressed as the 
number of antibiotic classes* received before VAP diagnosis. * β-
lactam antibiotics (penicillins and cephalosporins), carbapenems, fluor-
oquinolones, aminoglycosides, glycopeptides and linezolid, other anti-
biotics such as cotrimoxazole and colistin.Available online http://ccforum.com/content/12/6/R142
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Table 1
Characteristics of patients with ventilator-associated pneumonia caused by multidrug resistant (n = 52) and non-MDR (n = 140) 
pathogens*
Characteristics MDR (n = 52) Non-MDR (n = 140) p value
Demographics
Age, years 63 ± 13 58 ± 17 0.07
Male gender 41 (79%) 97 (69%) 0.37
Characteristics before VAP
Charlson index 2 (1 to 3) 1 (0 to 3) < 0.001
APACHE II upon ICU admission 22 ± 9 20 ± 9 0.37
Coma on ICU admission 6 (12%) 54 (39%) < 0.001
Shock on ICU admission 20 (38%) 56(40%) 0.87
ARDS before VAP 25 (48%) 29 (21%) 0.001
RRT before VAP 14 (27%) 18 (13%) 0.03
Duration of ventilation before VAP, days 9 (5 to 19) 7 (4 to 13) 0.008
Duration hospitalisation before VAP, days 0 (0 to 6) 0 (0 to 1) 0.001
Antibiotic exposure before VAP
No antibiotics 6 (11%) 32 (23%) 0.11
1 antibiotic class 15 (29%) 73 (52%) 0.005
2 antibiotic classes 13 (25%) 24 (17%) 0.22
> 2 antibiotic classes 18 (35%) 11 (8%) < 0.001
SOFA 2 days before VAP 5 (3 to 8) 5 (3 to 8) 0.83
Characteristics of VAP
SOFA at VAP 7 (3 to 10) 6 (4 to 9) 0.27
Delta SOFA 0.6 ± 3.3 0.6 ± 3.5 0.88
VAP with shock 15 (29%) 26 (19%) 0.16
Gram-negative aetiology 40 (77%) 122 (87%) 0.39
Enterobacteriaceae 28 (54%) 66 (46%) 0.07
Pseudomonas aeruginosa 11 (21%) 40 (29%) 0.98
Non-fermenter other than P. aeruginosa 1 (2%) 4 (3%) 0.32
Other Gram-negative† 0 12 (9%) 0.001
Gram-positive aetiology 12 (23%) 18 (13%) 0.39
Staphylococcus aureus 12 (23%) 13 (9%) 0.14
Streptococcus pneumoniae 0 5 (3%) 0.01
Appropriate therapy < 24 hours 41 (79%) 122 (87%) 0.16
Appropriate therapy < 48 hours 45 (87%) 133 (95%) 0.05
Subsequent VAP 10 (19%) 24 (17%) 0.83
Outcome parameters:
ICU-length of stay following VAP, days 18 (8 to 37) 15 (8 to 29) 0.34
Died 30 days after VAP diagnosis 19 (37%) 28 (20%) 0.02
Died at ICU 22 (42%) 29 (21%) 0.006
Died in hospital 28 (54%) 41 (29%) 0.001
Discharged to other hospital and lost to follow up 2 3
Referred to chronic health care facility 0 4
Still hospitalised at time of analysis 4 3
*Data are presented as mean ± SD, median (25th to 75th percentile) or number (%).
Delta SOFA: SOFA two days after VAP minus SOFA two days before VAP.
† Other Gram-negative: Haemophilus influenzae in 11, Moraxella catarrhalis in 1.
β-lactam antibiotics (penicillins and cephalosporins), carbapenems, fluoroquinolones, aminoglycosides, glycopeptides and linezolid, other 
antibiotics (cotrimoxazole, colistin).
APACHE = Acute Physiology and Chronic Health Evaluation; ARDS = acute respiratory distress syndrome; ICU, Intensive Care Unit; MDR, 
Multidrug-resistant; RRT, Renal Replacement Therapy; SOFA = sequential organ failure assessment; VAP, Ventilator-associated Pneumonia.Critical Care    Vol 12 No 6    Depuydt et al.
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Risk factors for 30 days mortality following VAP
Characteristics of nonsurvivors and survivors are shown in uni-
variate analysis in table 3. Results of the Fine and Gray regres-
sion model are shown in table 4. MDR bacterial aetiology was
not independently associated with mortality. Renal replace-
ment therapy before diagnosis of VAP (standardised hazard
ratio (SHR) = 2.69, 95% CI = 1.47 to 4.94, p = 0.001), the
Charlson index of comorbidity (SHR = 1.21, 95% CI = 1.03
to 1.41, p = 0.02) and shock on ICU admission (SHR = 1.86,
95% CI = 1.03 to 3.35, p = 0.04) were significant predictors
of 30-day mortality after VAP diagnosis.
Discussion
Only 3% of our patients were colonised with MDR pathogens
on ICU admission (as detected by our routine surveillance cul-
tures [23-25]) but MDR pathogens were involved in between
one-quarter and one-third of cases of VAP. This underscores
the pivotal role of the ICU as a specific nosocomial environ-
ment promoting the emergence and acquisition of MDR path-
ogens. A major determinant of the risk of MDR pathogens
causing VAP was previous antibiotic selection pressure: expo-
sure to more than two different classes of antibiotics since
hospital admission remained strongly associated with MDR
involvement after adjustment for exposure time and degree of
organ failure before diagnosis of VAP. Previous antibiotic
exposure has been identified as a risk factor for MDR microbial
aetiology of VAP in several studies [7,20,39,40]: our study
adds that this risk is especially high when a high 'burden' of
this selection pressure is present (figure 2).
Coma upon ICU admission showed a protective effect on the
risk of finding a MDR pathogen in VAP. This effect is likely
explained by the fact that in our cohort, coma as a covariate
identifies a subset which mainly consists of younger neuro-
trauma patients. As neurotrauma patients are at high risk for
early-onset VAP, our study design, where we only included the
first microbiologically confirmed episode of VAP, favoured this
association.
To test the hypothesis of whether a MDR microbial aetiology
of VAP was independently associated with increased 30-day
mortality after diagnosis of VAP, as compared with a non-MDR
bacterial cause, we performed a Fine and Gray regression
analysis, with discharge from the hospital alive as a competing
event to mortality. Survival analytic methods, such as Cox
regression analysis, have recently been challenged for their
appropriateness to evaluate ICU-mortality: the main criticism
applies to the fact that in order to yield correct results, censor-
ing must be independent of the outcome of interest (i.e. mor-
tality) [33-36]. If censoring results from ICU- or hospital
Table 2
Multivariable regression analysis of factors associated with the involvement of MDR pathogens in VAP (n = 192).
Predictor Parameter estimate OR CI p value
Enter method
Age 0.01 1.01 0.99 to 1.03 0.23
Charlson index 0.85 1.09 0.93 to 1.27 0.28
Coma on ICU admission -0.83 0.44 0.19 to 1.03 0.06
ARDS before VAP 0.52 1.69 0.86 to 3.31 0.13
RRT before VAP -0.42 0.66 0.31 to 1.42 0.29
Duration of hospitalisation before VAP 0.006 1.01 1.00 to 1.02 0.20
One antibiotic before VAP 0.06 1.06 0.39 to 2.92 0.90
Two antibiotic classes before VAP 0.85 2.34 0.82 to 6.71 0.11
More than two antibiotic classes before VAP 1.37 3.93 1.26 to 12.23 0.02
Constant -2.72
Backward stepwise
Coma on ICU admission -1.12 0.32 0.14 to 0.73 0.01
Two antibiotic classes before VAP 0.88 2.41 1.22 to 4.79 0.01
More than two antibiotic classes before VAP 1.50 4.47 2.15 to 9.31 < 0.001
Constant -1.50
Overall correct prediction: 77%.
Hosmer-Lemeshow goodness-of-fit: Chi-square 4.74, p = 0.8, eight degrees of freedom. ROC curve: area under the curve = 0.80 (0.73 to 0.86).
ARDS = acute respiratory distress syndrome; CI = confidence interval; ICU = intensive care unit; MDR = multidrug resistant; OR = odds ratio; 
RRT = renal replacement therapy; VAP = ventilator-associated pneumonia.Available online http://ccforum.com/content/12/6/R142
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discharge, this assumption is not correct, as patients dis-
charged alive are at much lower risk of mortality than patients
remaining at the ICU. This problem is bypassed by multivariate
logistic regression analysis, but here crucial information may
be lost as the time to death is not taken into account. The Fine
and Gray analysis, although closely related to logistic regres-
sion, extends this model by incorporating different exposure
times in the ICU. Using the Fine and Gray model, the associa-
tion between increased (cumulative) 30-day mortality follow-
ing MDR versus a non-MDR VAP diagnosis was no longer
Table 3
Variables associated with 30-day mortality after VAP diagnosis in univariate analysis (n = 192)*
Characteristics Nonsurvivors (n = 47) Survivors (n = 145) p value
Demographics
Age 62 ± 14 58 ± 17 0.12
Male gender 14 (30%) 40 (28%) 0.71
Characteristics before VAP
Charlson index 2 (1 to 3) 1 (0 to 3) 0.01
APACHE II on ICU admission 20 ± 8 21 ± 9 0.87
Shock on ICU admission 26 (55%) 50 (35%) 0.016
ARDS 21 (45%) 33 (23%) 0.005
RRT before VAP 17 (36%) 15 (10%) < 0.001
Duration of mechanical ventilation before VAP, days 9 (5 to 16) 7 (3 to 14) 0.14
Number of infectious episodes before VAP 1 (1 to 1) 1 (1 to 1) 0.243
SOFA 2 days before VAP 7 (5 to 9) 5 (3 to 7) 0.001
Characteristics at diagnosis of VAP
SOFA at VAP 9 (5 to 11) 5 (4 to 8) < 0.001
Delta SOFA 1 (0 to 4) 0 (-1 to 1) < 0.001
VAP with shock 19 (40%) 22(15%) < 0.001
Microbial aetiology of VAP
MDR aetiology 19 (40%) 33 (23%) 0.02
Gram-negative aetiology 40 (85%) 122 (84%) 0.39
Enterobacteriaceae 24 (62%) 70 (48%) 0.71
Pseudomonas aeruginosa 12 (26%) 39 (27%) 0.84
Non-fermenter other than P. aeruginosa 3 (6%) 2 (1%) 0.006
Other Gram-negative† 1(2%) 11 (8%) 0.001
Gram-positive aetiology 7(15%) 23(16%) 0.39
Staphylococcus aureus 7 (15%) 18 (12%) 0.37
Streptococcus pneumoniae 05  ( 4 % ) 0 . 0 1
Subsequent VAP 4 (9%) 30(21%) 0.08
Treatment characteristics
Appropriate therapy < 24 hours¶ 38 (83%) 125(86%) 0.63
Appropriate therapy < 48 hours¶ 43 (94%) 135 (93%) 0.99
*Data are presented as mean (± SD), median (25th to 75th percentile) or number (%).
Delta SOFA: SOFA two days after VAP minus SOFA two days before VAP.
† Other Gram-negative: Haemophilus. influenzae in 11, Moraxella catarrhalis in 1.
¶Data about antibiotic therapy were available in 187 patients (50 nonsurvivors and 137 survivors).
APACHE = Acute Physiology and Chronic Health Evaluation; ARDS = acute respiratory distress syndrome; ICU, Intensive Care Unit; MDR, 
Multidrug-resistant; RRT, Renal Replacement Therapy; SOFA = sequential organ failure assessment; VAP, Ventilator-associated Pneumonia.Critical Care    Vol 12 No 6    Depuydt et al.
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significant after appropriate adjustment for comorbidity and
some measures of more severe critical illness, such as shock
on ICU admission, underlying ARDS and severe acute kidney
injury requiring renal replacement therapy. As such, the isola-
tion of MDR versus other pathogens in our study behaved as
a marker of a category of patients with a lower a priori chance
of ICU survival.
The lack of association between antimicrobial resistance and
mortality has also been observed by Combes and colleagues
in patients with VAP caused by P. aeruginosa and S. aureus
[16,17], and by Blot and colleagues in patients with Gram-
negative bacteraemia [41]. In contrast, in a retrospective study
on bacteraemic VAP, MRSA and MDR P. aeruginosa were
independently associated with increased mortality [24]. As
this retrospective study consisted of more severely ill patients
with a higher mortality rate, a possibility remains that the
impact of MDR varies according to different categories of
patients. Alternatively, residual confounding may be of con-
cern in this study, because underlying critical illness at diagno-
sis of VAP was not accounted for. Part of the controversy of
whether involvement of MDR in nosocomial infection is an
independent risk factor for mortality possibly stems from inclu-
sion of different sets of covariates in regression models or from
different matching criteria in matched cohort studies. When
assessing the impact of MDR on outcome, measures of sever-
ity of illness more close to the time of diagnosis of VAP, rather
than on ICU admission, probably allow for better adjustment in
multivariable regression or for better balancing patient cohorts
in a matched cohort analysis [18,42]. Yet, care must be taken
to assess severity of illness sufficiently before the onset of
VAP, because incipient VAP itself may increase the measure
of severity of illness.
Acute kidney injury requiring renal replacement therapy pre-
ceding development of VAP was an independent predictor of
mortality. An excess mortality associated with the requirement
for renal replacement therapy in ICU patients has been
recently demonstrated in a large multicentric matched cohort
analysis [43]. Early appropriate antibiotic therapy on the other
hand was not associated with mortality. This lack of associa-
tion is probably due to underpowering as few patients
received inappropriate therapy: appropriate antibiotics were
administered within 24 hours and within 48 hours in 85% and
93% of episodes, respectively, and in the subgroup of patients
with septic shock, in which early appropriate antibiotic therapy
may have the greatest impact [13], these figures were 90%
and 100%, respectively.
Our study has several limitations. Firstly, determinants of MDR
were identified using a case-control design, with patients with
VAP caused by non-MDR pathogens as controls rather than
patients at risk of developing VAP (source patients). As antibi-
otic exposure is likely to suppress the growth of susceptible
bacteria, these control patients may have received fewer anti-
biotics than the overall source patients, leading to overestima-
tion of the association between antibiotic exposure and MDR
[44]. Other bias caused by different time-at-risk and comorbid-
ity was reduced by our multivariable analysis, adjusting for
duration of prior hospitalisation and the Charlson index of
comorbidity, but bias may not have been completely elimi-
nated. However, it is more likely that insufficient elimination of
confounding would have lead to a detection of a false associ-
ation than obscuring a real association. Secondly, as we
defined MDR as a set of pathogens rather than antibiotic
resistance in a single microbial species, our study may be
underpowered to detect the possible deleterious impact of
Table 4
Fine and Gray multivariate analysis of factors associated with 30-day mortality after VAP diagnosis (n = 192). The five variables 
selected on the basis of univariate analyses (n = 192).
Predictor Parameter estimate SHR CI p value
Enter method
MDR aetiology 0.33 1.39 0.77 to 2.50 0.28
ARDS before VAP 0.42 1.52 0.83 to 2.79 0.18
RRT before VAP 0.79 2.20 1.18 to 4.13 0.01
Charlson index of comorbidity 0.18 1.20 1.02 to 1.40 0.04
Shock on ICU admission 0.55 1.73 0.96 to 3.12 0.07
Forward and backward stepwise
RRT before VAP 0.99 2.69 1.18 to 4.28 0.001
Charlson index of comorbidity 0.19 1.21 1.03 to 1.41 0.02
Shock on ICU admission 0.62 1.73 1.03 to 3.35 0.04
ARDS = adult respiratory distress syndrome; CI = confidence interval; ICU = intensive care unit; MDR = multidrug resistant pathogen; RRT = 
renal replacement therapy; SHR = subdistribution hazard ratio; VAP = ventilator-associated pneumonia.Available online http://ccforum.com/content/12/6/R142
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MDR in VAP caused by a single microbial species, such as S.
aureus  of  P. aeruginosa. Similarly, elucidating the relation
between patterns of antimicrobial resistance encountered in
pathogens causing VAP and previous antimicrobial prescrip-
tion would require a larger and preferably multicentric study.
Although our current approach may have lead to missing a sig-
nificant association between antibiotic resistance in a particu-
lar pathogen and outcome, at the very least this could not be
detected in our three-year dataset derived from a large tertiary
ICU with a resistant microbial flora. We believe therefore that
even if such an association was present, the strength of such
association was probably small.
Secondly, the small sample size permitted the inclusion of only
a limited number of covariates in our multivariate analysis.
However, as the aim of our study was primarily to test whether
MDR is independently associated with mortality, finding at
least one regression model where MDR was not a significant
predictor was sufficient to falsify the null-hypothesis.
Conclusion
In our cohort of patients with VAP, exposure to more than two
antibiotic classes after hospital admission was identified as
the most important risk factor for a MDR microbial aetiology of
VAP. A MDR, as compared with a non-MDR, bacterial cause
of VAP was not an independent risk factor for ICU-mortality in
a setting where rates of early appropriate antibiotic therapy
were high.
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